

## DAFTAR PUSTAKA

1. American Cancer Society. Ovarian cancer. <https://www.cancer.org/content/dam/CRC/PDF/Public/8773.00.pdf> - Diakses 25 Juli 2019
2. Ariningtyas ND. CA 125 dan Pemakaian Klinis dalam Penatalaksanaan Kanker Ovarium. *Qanun Medika*. 2018;2(2):73-81
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E386
4. WHO(2010), GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. World Health Organization.<http://globocan.iarc.fr/> - Diakses Januari 2019
5. Kumar S, Munkarah A, Arabi H, Bandyopadhyay S, Semaan A, Hayek K, et al. Prognostic analysis of ovarian cancer associated with endometriosis. *Am J Obstet Gynecol*.2011;204(1):63.e1-7.
6. Marice Sihombing AMS. Angka Ketahanan Hidup Penderita Kanker Ovarium di RS Dr. Cipto Mangunkusumo Jakarta. *Majalah Kedokteran Indonesia*, V. 2010;57(10):348–70.
7. Hoffman LB, Schorage JO, Schaffer JI, Halvorson LM, Bradshaw KD, Corton MM. *Williams Gynecology*. 3rd Edition. New York : McGraw-Hill Companies;2016
8. Dewi M. 2017. Sebaran kanker di Indonesia Riset Kesehatan Dasar. *Indonesian Journal of Cancer*. 11(1): 1-8
9. Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M, Salehiniya H. The incidence and mortality of ovarian cancer and their relationship with the human development index in asia. *E Can Med Science*. 2016 ; 10: 628
10. Kementrian Kesehatan RI. INFODATIN Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi Penyakit Kanker. 2015 <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf> - Diakses 25 Juli 2019

11. Aziz MF. Gynecological Cancer in Indonesia. *J Gynecol Oncol.* 2009; 20(1): 8-10.
12. Dewi M. Sebaran Kanker di Indonesia, Riset Kesehatan Dasar 2007. <https://indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/494/242>- Diakses 25 Juli 2019
13. Dhitayoni IA, Budiana NG. Profil pasien kaker ovarium di Rumah Sakit umum pusat Sanglah Denpasar-Bali Periode Juli 2013-Juni 2014. *E-Jurnal Medika.* 2017;6(3):1-9
14. Hirst J, Crow J, Godwin A. Ovarian Cancer Genetics: Subtypes and Risk Factor. *IntechOpen.* 2018:1-38
15. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao X, et al. Ovarian cancer: pathology, biology, and disease models. *Front Biosci.* 2009;14:2089-2102
16. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. *Am J Obstet Gynecol.* 1997;176:572-9.
17. Melin A, Sparén P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. *Human Reprod.* 2006;21(5):1237-42.
18. Vlahos NF, Kalampokas T, Fotiou S. Endometriosis and ovarian cancer: a review. *Gynecol Endocrinol.* 2010;26(3):213-9.
19. Giudice LC, Kao LC. Endometriosis. *Lancet.* 2004;364(9447):1789-99.
20. Bulun SE. Endometriosis. *N Engl J Med.* 2009;360(3):268-79.
21. Nezhat F, Apostol R, Mahmoud M, Daouk M el. Malignant transformation of endometriosis and its clinical significance. *Fertil Steril.* 2014;102(2):2-4.
22. Zafrakas M, Grimbizis G, Timologou A, Tarlatzis BC. Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies. *Front Surg.* 2014;1(14):1-6.
23. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. *Fertil Steril* 2004;82(2):405-14

24. Kobayashi H, Sumimoto K, Moniwa N, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. *Int J Gynecol Cancer*. 2007;17(1):37-43
25. Gupta S, Harlev A, Agarwal A, Gupta A, Grey M, Pandithura E, et al. Endometriosis and Ovarian Cancer. In: *Endometriosis, A comprehensive Update*. Gupta S, Harlev A, Agarwal A, editors. New York: Springer; 2015. P61-74.
26. Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: links, risks, and challenges faced. *Int J Womens Health*. 2015;7:663-672.
27. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. *Eur J Cancer*. 2008;44(16):2477-84.
28. Tang H, Liu Y, Wang X, Guan L, Chen W, Jiang H. Clear cell carcinoma of the ovary: clinicopathologic features and outcomes in a Chinese cohort. *Medicine*. 2018;97(21):1-7
29. Bell DA. Origins and molecular pathology of ovarian cancer. *Mod Pathol*. 2005;18:S19-S32.
30. Somigliana E, Vigano' P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence. *Gynecol Oncol*. 2006;101(2):331-41.
31. Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. *Fertil Steril*. 2008; 90(5):1559-70.
32. Thomsen LH, Schnack TH, Buchardi K, Hummelshoj L, Missmer SA, Forman A, et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. *Acta Obstet Gynecol Scand*. 2017;96(6):761-778
33. Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T. Endometriosis-associated Malignancy. *Geburtsh Frauenheilk*. 2016;76(2):176-81.

34. Purdie DM, Bain CJ, Sinkind V, Webb PM, Green AC. Ovulation and Risk of Epithelial Ovarian Cancer. *Int J Cancer*.2003;104(2),228–232.
35. Tung K, Goodman MT, Wu AH, McDuffie K, Wilkens L, Kolonel L, et all. Reproductive Factors and Epithelial Ovarian Cancer Risk by Histologic Type: A Multiethnic Case-Control Study. *Am J Epidemiol*. 2003;158(7):629-638
36. Fathalla MF. Incessant ovulation and ovarian cancer a hypothesis revisited. *Fact Views Vis Obgyn*. 2013;5(4): 292-7.
37. Prawirohardjo S. Buku Acuan Nasional Onkologi Ginekologi: edisi 1. Aziz MF, Andrijono, Saifuddin AB, editor. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo, 2006.
38. Prawirohardjo S. Buku Acuan Nasional Onkologi Ginekologi: edisi 1. Aziz MF, Andrijono, Saifuddin AB, editor. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo, 2006.
39. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. *Am J of Obstet and Gynecol*. 2004. 191(3):733-40.
40. Melin A, Sparen P, Bergqvist. The risk of cancer and the role of parity among women with endometriosis. *Hum Reprod*. 2007;22(11):3021-26.
41. zanetta GM,Webb MJ, Li H, Keeney GL. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. *Gynecol Oncol*. 2000;79(1):18-22
42. Fachlevy AF, Abdullah Z, Russeng SS. Faktor risiko kanker ovarium di RSUP Wahidin Sudirohusodo Makasar. Makasar:Universitas Hasanuddin; 2012 (Diakses 11 Maret 2019). Tersedia dari: <http://pasca.unhas.ac.id/jurnal/files/bca0c5c2aa0abea0b3f749d864cf246a.pdf>.
43. Worley Jr. MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-Associated Ovarian Cancer: A Review of Pathogenesis. *Int J Mol Sci*. 2013;14(3):5367-5379
44. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K. Oral contraceptive use and reproductive factors and risks of ovarian cancer in

- Europeana Prospective Investigation into cancer and nutrition. *Br J Cancer*. 2011;105(9):1436-42.
45. Kadan Y, Fiascone S, McCourt C, Raker C, Granai CO, Steinhoff M. Predictive factors for the presence of malignant transformation of pelvic endometriosis. *Eur J Obstet Gynecol Rep Biol*. 2015;185:23-27.
46. Roche. *Oncology. Ovarian Cancer Guide*. 2015. <http://www.roche.com/med-ovarian-cancer.pdf>, diakses September 2018
47. Fauzan R. Gambaran faktor risiko penggunaan kontrasepsi terhadap angka kejadian kanker ovarium di RSUPN Dr. Cipto Mangunkusumo Jakarta berdasarkan pemeriksaan histopatologik. (Tesis). Jakarta :Universitas Indonesia, 2009
48. Schorge JO, Young RH, Birrer MJ, del Carmen M.. *Uncommon Gynecologic Cancer*. First Edition. Chichester: John Wiley & Son;2015. 53-63
49. Simamora, RPA. Hubungan usia, jumlah paritas dan usia menarche terhadap derajat histopatologi kanker ovarium di RSUP Dr. H. Abdul Moelok Bandar Lampung tahun 2015-2016.(skripsi). Bandar Lampung: Universitas Lampung,2018
50. Tadashi T. No evidence of endometriosis within serous and mucinous tumors of the ovary. [Int J Clin Exp Pathol](#). 2012; 5(2): 140–142.
51. American Cancer Society (ACS). *Cancer Facts and Figures 2007*. Atlanta, American Cancer Society;2007.
52. Sofoudis C. Ovarian Clear Cell Carcinoma: Metastatic Pathways. *IntechOpen*.2018:115-124
53. Prawirohardjo S. Ilmu kandungan: edisi 3. Anwar M, Baziad A , Prabowo RP, editor. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo, 2014. P. 242
54. Suparman E. Penatalaksanaan endometriosis. *Biomedik*. 2012;4:69-78.
55. Mukti P. Faktor Risiko Kejadian Endometriosis. *Unnes Journal of Public Health*. 2014;3(3):1–10.
56. Hendarto H. *Endometriosis dari aspek teori sampai penanganan klinis*. Surabaya: Airlangga University Press, 2015.

57. Perkumpulan Obstetri dan Ginekologi Indonesia. Konsensus tatalaksana nyeri haid pada endometriosis: Himpunan Endokrinologi-Reproduksi dan Fertilitas Indonesia; 2013.
58. Hoffman LB, Schorage JO, Schaffer JI, Halvorson LM, Bradshaw KD, Cunningham FG. Williams Gynecology. 2nd Edition. New York : McGraw-Hill Companies;2012
59. Wiweko B, Puspita CG, Sumapraja K, Natadisastra M, Harzief AK, Situmorang H, et al.. Pilihan Penanganan Terkini Pada Endometriosis. *Medicinus*. 2013;26(2),5-7.
60. Limbong, Vinanda MA, 2012. Profil Gambaran Endometriosis di RSUP H. Adam Malik Periode 2008-2011. Skripsi. Medan : Fakultas Kedokteran Universitas Sumatera Utara.
61. Chapron C, Fauconnier A, Dubuisson JB, *et al.*. Deep infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of disease. *Hum Reprod*.2003;18(4):760-6.
62. Nurcahyo RA. Studi Perbedaan Ekspresi BAX antara Endometriosis Ovarii (Endometrioma) dan Karsinoma Ovarii Serosum Diferensiasi Baik. (Tesis). Surakarta :Universitas Sebelas Maret. 2010
63. Neyland L, Casper R, Laberge P, Singh SS. Endometriosis: Diagnosis and Management. *J Obstet Gynaecol Can*. 2010;32(7):S26–8.
64. *Endometriosis - Basic Concepts and Current Research Trends*. Chaudhury K, Chakravarty B, Editor. Croatia; InTech, 2012.
65. Wu IB, Tendean HMM, Mewengkang ME. Gambaran Karakteristik Penderita Endometriosis di RSU Prof Dr. R. D. Kandou Manado. *Jurnal e-Clinic*.2017;5(2):279-285.
66. pangemanan G, Loho M, Wagey FW. Profil Penderita Endometriosis di RSUP Prof Dr. R.D. Kandou Manado pada tahun 2011-2015. *Jurnal e-Clinic*. 2017;5(1):16-21
67. Lisnawati. Gambaran faktor-faktor risiko penderita kanker ovarium di RSUD Labuang Baji Makasar Tahun 2013. (skripsi). Makasar: Universitas Islam Negeri Alauddin Makasar, 2014

68. Kobayashi H, Sumimoto K, Kitanaka T, Yamada Y, Sado T, Sakata M, et al. Ovarian endometrioma-Risk factors of ovarian cancer development. *Eur J Obstet Gynecol Reprod Biol.* 2008;138(2):187-193.
69. American Cancer Society. Ovarian Cancer Overview. <https://www.cancer.org/cancer/ovarian-cancer/causes-risks-prevention/risk-factors.html>. Diakses Maret 2019
70. Octavianny A. Hubungan kista endometriosis dengan kejadian infertilitas di RSUD Tugurejo Semarang dan RSUD Kota Semarang. (Skripsi). Semarang :Universitas Muhammadiyah Semarang. 2016
71. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. *Br J Cancer.* 2001;84(5):714-721.
72. Boyraz G, Selcuk I, Yazicioglu A, Tuncer ZS. Ovarian Carcinoma Assocoated with Endometriosis. *Eur J Obstet Gynecol Reprod Biol.*2013;170(1):211–213
73. Wijaya I. Hubungan kadar CA 125, HEA dan Indeks Morfologi Usg dengan Kanker Ovarium Tipe Epitelial masa premenopause. (Tesis). Denpasar :Universitas Udayana, 2017
74. Heidemann LN, Hartwell D, Heidemann CH, Jochumsen KM. The relation between endometriosis and ovarian cancer- a review. *Acta Obstet Gynecol Scand.* 2014;93(1);20-31.
75. Russell P. The pathological assessment of ovarian neoplasms. II: The proliferating “epithelial” tumours. *Pathology.* 1979;11(2):251–82.
76. Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. *Int J Gynecol Obstet.* 1997;59(3):245–50.
77. Muangtan S, Suknikhom W, Sananpanichkul P. Epithelial ovarian cancer with endometriosis is not associated with menopausal status: A co-association study at Prapokklao Hospital. *Asian Pac J Cancer Prev.* 2018;19(5):1337–41.
78. Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and

- breastfeeding in the prospective Million Women Study. *Int J Cancer*. 2018;142(2):281–9.
79. Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, et al. Factors Influencing Ovulation and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. *Int J Cancer*. 2015;137(5):1136–46.
80. Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women's health. *Epidemiol Rev*. 1995;17(2):265–86.
81. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. *Am J Epidemiol*. 1983;117(2):128–39.
82. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. *Acta Obstet Gynecol Scand*. 2004;83(9):783–95.
83. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 carrier cohort study. *Cancer Epidemiol Biomarkers Prev*. 2009;18(2):601–10.
84. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: Systematic review and meta-analysis. *J Natl Cancer Inst*. 2014;106(6).
85. Esmaili H, Vahedi A, Mohajeri S, Mostafidi E, Azimpouran M, Behzad MN. Evaluation of the pathogenesis of tumor development from endometriosis by estrogen receptor, P53 and bcl-2 immunohistochemical staining. *Asian Pacific J Cancer Prev*. 2016;17(12):6147–50.
86. Shen YM, Wu XL, Xu L, Huang Q, Yu N, Yao XY, et al. Malignant transformation of ovarian endometriosis: a clinicopathologic analysis of 49 cases. *Ai Zeng*. 2008;27(10):1106–10
87. Taniguchi F. New knowledge and insights about the malignant transformation of endometriosis. *J Obstet Gynaecol Res*. 2017;43(7):1093–100.
88. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. *Am J Epidemiol*. 2007;166(8):894–901.



89. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. *N Engl J Med*. 1998; 339(7):424-428.
90. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women. *JAMA*. 2001;285(11):1460–1465.
91. [Riman T](#), [Dickman PW](#), [Nilsson S](#), [Correia N](#), [Nordlinder H](#), [Magnusson CM](#), et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. *Am J Epidemiol*. 2002; 156(4):363-73.

